Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Zscaler Inc (ZS) Price & Performance

BridgeBio Pharma IncTrade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Zscaler Inc — how do they compare? BridgeBio Pharma Inc trades at $84.74 (market cap $16.36B), while Zscaler Inc trades at $177.1 (market cap $28.87B). The key difference: Zscaler Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.

BBIOZS
Market Cap
$16.36B$28.87B
Sector
HealthTechnology
52-Week High
$90.17$336.27
52-Week Low
$47.29$118.05
Enterprise Value
$18.14B$27.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Zscaler Inc

Zscaler (ZS) trades at $176.68, up 4.74% with strong technical momentum and bullish analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though profitability remains negative with a -2.44% net margin. Recent earnings beats and leadership in Gartner's Magic Quadrant for security platforms support positive momentum, while elevated valuation ratios (P/S 8.94, EV/EBITDA 188.83) reflect growth expectations.

Outlook remains cautiously optimistic with 79% analyst buy ratings and $191.81 consensus target, but risks include persistent unprofitability, high spending, and competitive pressures. The upcoming Q2 2026 earnings report on September 3 will be critical for validating growth trajectory amid concerns about execution and valuation sustainability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS